Cjc-1295 No Dac

Overview and Structural Biochemistry of CJC-1295 No DAC

In peptide chemistry, CJC-1295 No DAC—frequently designated as Modified GRF 1-29—represents a tetrasubstituted derivative of the natural growth-hormone-releasing hormone fragment GHRH(1-29). Native GHRH is a 44-amino-acid peptide produced by the hypothalamus, but its core biological activity resides within the initial N-terminal 29-amino-acid sequence. Native GHRH(1-29) exhibits a very short biological half-life in laboratory models due to rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) between the Alanine-2 and Aspartate-3 positions.

To mitigate rapid enzymatic degradation, chemical syntheses introduced specific amino acid substitutions at key positions. In CJC-1295 No DAC, the native peptide sequence is modified at position 2 (D-Alanine replacing L-Alanine), position 8 (Glutamine replacing Asparagine), position 15 (Alanine replacing Glycine), and position 27 (Leucine replacing Methionine). These strategic modifications confer resistance to DPP-IV enzymatic cleavage while maintaining high binding affinity for the pituitary GHRH receptor.

Unlike variants conjugated with a Drug Affinity Complex (DAC), high-purity CJC-1295 No DAC lyophilisates lack the reactive maleimido-propionic acid bioconjugate. Consequently, CJC-1295 No DAC does not covalently bind to endogenous serum albumin, allowing it to clear rapidly from systemic circulation following receptor activation and preserving natural, physiological pulsatility.

GHRH Receptor Binding Dynamics and Intracellular Signaling

The primary mechanism of action for CJC-1295 No DAC centers on its selective agonist activity at the growth-hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor predominantly expressed on the cell membrane of anterior pituitary somatotropes. In vitro assays demonstrate that binding of CJC-1295 No DAC to GHRHR triggers a conformational change that stimulates the Gs alpha subunit of the heterotrimeric G protein complex.

Activation of Gs alpha stimulates membrane-bound adenylyl cyclase, resulting in an intracellular surge of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels activate protein kinase A (PKA), which subsequently phosphorylates specific transcription factors, such as the cAMP response element-binding protein (CREB). This signaling cascade stimulates both the gene transcription of growth hormone and the exocytosis of pre-stored GH secretory vesicles into extracellular media.

Preclinical studies suggest that GHRHR signaling also activates the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in pituitary somatotropes. These complementary cascades promote cellular survival and maintain structural somatotrope integrity, providing a robust framework for investigating pituitary cell biology in vitro.

Pulsatile GH Secretion Patterns: No DAC vs. Continuous Elevation

Endogenous growth hormone secretion in mammals is naturally pulsatile, characterized by distinct periodic spikes separated by low baseline concentrations. Research models evaluating growth hormone dynamics differentiate sharply between continuous continuous GHRH exposure and discrete GHRH stimulation pulses. CJC-1295 No DAC exhibits a biological half-life of approximately 15 to 30 minutes in rodent models, making it ideal for investigating pulsatile GH dynamics.

In contrast, variants containing the Drug Affinity Complex form long-lasting covalent bonds with circulating albumin, extending half-life significantly and maintaining continuous GHRH receptor stimulation over several days. While continuous exposure leads to steady-state baseline elevations of growth hormone, it can also lead to GHRH receptor desensitization or downregulation in certain animal models.

Because CJC-1295 No DAC undergoes natural systemic clearance, laboratory assays show that pituitary somatotropes recover baseline receptor sensitivity between exposure intervals. Researchers seeking to study natural circadian rhythmicity or physiological pulse patterns generally select non-conjugated GHRH analogs to avoid persistent receptor occupancy. For investigations requiring continuous plasma concentrations, researchers often compare these findings against the longer-acting CJC-1295 DAC variant.

Preclinical Literature on Downstream IGF-1 and Tissue Repair Pathways

In laboratory models, GHRH-induced somatotropic release of growth hormone acts upon hepatic tissue to stimulate the transcription and systemic secretion of Insulin-like Growth Factor 1 (IGF-1). IGF-1 serves as a principal mediator for cell proliferation, protein synthesis, and extracellular matrix remodeling across a wide spectrum of tissue types.

In vitro data indicate that elevated local concentrations of IGF-1 secondary to GHRH analog administration upregulate mRNA expression for Type I and Type III collagen in musculoskeletal tissue explants. Preclinical rodent models investigating wound healing and connective tissue repair demonstrate that increased IGF-1 signaling accelerates fibroblasts migration, enhances satellite cell activation in striated muscle, and promotes osteoblast proliferation in bone remodeling studies.

Furthermore, animal models evaluating metabolic parameters under GHRH analog regimens show alterations in nitrogen retention, lipolysis kinetics, and cellular glucose uptake. Data cataloged in the PX1 research library hub highlight how these somatotropic axis modulations provide valuable insights into metabolic homeostasis and cellular regeneration mechanisms.

Synergistic Co-Administration Protocols with Ghrelin Mimetics

Growth hormone secretion is dual-regulated by two distinct hypothalamic pathways: GHRH acting upon the GHRH receptor, and ghrelin acting upon the growth hormone secretagogue receptor (GHSR-1a). Preclinical research frequently investigates the synergistic interaction between GHRH analogs and GHSR agonists in vitro and in vivo.

When CJC-1295 No DAC is co-administered in research models alongside a selective GHSR agonist such as ipamorelin, the observed secretion of growth hormone exceeds the simple additive mathematical sum of each compound administered individually. This phenomenon, known as secretagogue synergy, occurs because GHSR activation inhibits endogenous somatostatin release (the primary GH inhibitor) while simultaneously enhancing intracellular calcium influx, permitting maximum cAMP-mediated GH vesicle release triggered by GHRH receptor stimulation.

Comparative co-administration studies also incorporate classic hexapeptide secretagogues like ghrp-6 to map out differences in receptor selectivity, prolactin secretion, and cortisol release dynamics across various secretagogue classes.

Comparative Analysis Across GHRH Signaling Compounds

To select the appropriate experimental model, researchers must evaluate how CJC-1295 No DAC compares to other GHRH receptor agonists within the same functional family. While all GHRH analogs target the pituitary GHRH receptor, structural variations directly dictate enzymatic half-life, receptor affinity, and physiological kinetics in animal models.

For instance, sermorelin retains the native GHRH(1-29) sequence without enzymatic substitutions, resulting in a rapid in vivo half-life of 8–12 minutes due to swift DPP-IV degradation. CJC-1295 No DAC (Modified GRF 1-29) incorporates four strategic amino acid substitutions that resist DPP-IV enzymatic cleavage, extending its functional half-life to approximately 15–30 minutes while preserving discrete pulsatile clearance. Conversely, CJC-1295 DAC appends a maleimido-propionic acid complex that binds serum albumin, extending systemic circulation to over 6–8 days and producing continuous baseline GH elevation rather than physiological pulses.

Laboratory Reconstitution, Preparation, and Handling Protocols

Proper handling and preparation of lyophilized peptides are critical to maintaining structural integrity and experimental reproducibility. Laboratory protocols for handling the CJC-1295 No DAC peptide mandate aseptic technique within a certified laminar flow hood to prevent microbial contamination.

Reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile physiological saline, depending on the requirements of the specific cell culture or assay system. The diluent should be introduced down the glass vial wall rather than sprayed directly onto the lyophilized cake to avoid agitation-induced mechanical shearing of the peptide chain. Gently swirl the vial until the powder is fully dissolved; never vortex.

Once reconstituted, peptide solutions should be aliquoted into single-use polypropylene microtubes to prevent repeated freeze-thaw cycles, which induce aggregation and degradation. Reconstituted solutions remain stable at 2°C to 8°C for short-term evaluation (up to 30 days when using bacteriostatic media), while un-reconstituted lyophilized vials should be stored at -20°C or -80°C for long-term storage.

Quality Control, Analytical Verification, and Supplier Metrics

Preclinical data integrity depends fundamentally on the chemical purity and consistency of research compounds. PX1 Research enforces rigorous quality assurance metrics across every synthesis lot, ensuring that researchers receive compounds verified to meet strict analytical criteria.

Every lot of CJC-1295 No DAC undergoes dual analytical verification. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) confirms chemical purity exceeding 98.0%, ensuring the absence of truncated sequences or synthesis side-products. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise molecular weight matching the theoretical mass of 3367.9 Da.

Furthermore, all lots are subjected to Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg, preventing confounding inflammatory responses in cell culture or animal assays. Manufactured in USA-based, GMP-compliant facilities and tested by ISO 17025 accredited laboratories, complete lot-traceable COAs are available for every item in our catalog of all peptides. Institutional laboratories requiring bulk volume allocations can access verified reagents directly through our wholesale portal.